Medical device company DexCom (NASDAQ:DXCM) reported Q1 CY2026 results , with sales up 15% year on year to $1.19 billion. The ...

If you are wondering whether DexCom shares are priced attractively right now or if the stock still carries a premium, this article breaks down what the current market price might be implying about the ...

DexCom (NASDAQ:DXCM) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, ...

Pre-earnings options volume in DexCom (DXCM) is 2.4x normal with puts leading calls 7:5. Implied volatility suggests the market is anticipating a move near 6.7%, or $5.59, after results are released.

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the CGM market. A strong third-quarter 2025 performance and a series of favorable coverage decisions ...

DexCom stock (NASDAQ: DXCM) currently trades at $73 per share, around 55% below the highs of $163 seen in November 2021. In comparison, Insulet stock (NASDAQ: PODD) saw its stock decline 39% over the ...

The company is presenting several abstracts during the five-day conference showcasing clinical and real-world evidence that support the benefits of its products. Dexcom is presenting several abstracts ...